Bio 54, LLC, is the first portfolio company of 501 Ventures, LLC. It recently closed on its Series A to advance the IP for a drug/device combination product to treat excessive bleeding in patients on anticoagulants/anti-platelet therapies. Clinical studies will begin in 1H 2023.
501 Ventures, LLC is a Life Science Accelerator based in Chapel Hill, NC. Founded by a group of entrepreneurs and Life Science executives, 501 Ventures seeks to bring efficiency to drug development by sharing the management team across multiple portfolio companies as well as conducting the majority of clinical work in house. Our primary focus is non-oncology, small molecule products that are between 18 months to the clinic through Phase 2.